000 02841nam a22005055i 4500
001 u377899
003 SIRSI
005 20160812084526.0
007 cr nn 008mamaa
008 100907s2010 ne | s |||| 0|eng d
020 _a9789048190577
_9978-90-481-9057-7
040 _cMX-MeUAM
050 4 _aR-RZ
082 0 4 _a610
_223
100 1 _aShlaes, David M.
_eauthor.
245 1 0 _aAntibiotics
_h[recurso electrónico] :
_bThe Perfect Storm /
_cby David M. Shlaes.
264 1 _aDordrecht :
_bSpringer Netherlands :
_bImprint: Springer,
_c2010.
300 _aVIII, 106 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _a1 The Perfect Storm -- 2 The Miracle -- 3 Resistance – The miracle is fading -- 4 The FDA – We need them, but they have become part of the problem -- 5 Europe -- 6 The Pharmaceutical Industry – after a glorious history, the industry is now struggling on all fronts -- 7 Modest Proposals -- 8 Conclusions.
520 _aAntibiotics are truly miracle drugs. As a class, they are one of the only ones that actually cure disease as opposed to most drugs that only help relieve symptoms or control disease. Because bacteria that cause serious disease in humans are becoming more and more resistant to the antibiotics we have today, and because they will ultimately become resistant to any antibiotic that we use for treatment or for anything else (like crops, animals, etc.), we need a steady supply of new antibiotics active against the resistant bacteria that arise. But the antibiotics marketplace is no longer attractive for large pharmaceutical companies, the costs of development are skyrocketing because of ever more stringent requirements by the regulatory agencies and finding new antibiotics active against resistant strains is getting harder and harder. These forces are all combining to deny us these miracle drugs when we need them the most. I provide a number of possible paths to shelter from this perfect storm.
650 0 _aMedicine.
650 0 _aImmunology.
650 0 _aDrug interactions.
650 0 _aToxicology.
650 0 _aBiotechnology.
650 0 _aPharmacy.
650 1 4 _aBiomedicine.
650 2 4 _aBiomedicine general.
650 2 4 _aImmunology.
650 2 4 _aDrug Resistance.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aBiotechnology.
650 2 4 _aPharmacy.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789048190560
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-90-481-9057-7
596 _a19
942 _cLIBRO_ELEC
999 _c205779
_d205779